Cathepsin W (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Cathepsin W (CTSW/Lymphopain, UniProt P56202) expressed in HEK293 cells. Used in cysteine protease activity assays, inhibitor profiling, and as a positive control standard for antibody validation.
Expression system
HEK293
Cat. #
REC-CathepsinW

In stock

SKU
REC-CathepsinW
$498.00

Target Overview

Cathepsin W (UniProt P56202; gene CTSW) is a cysteine protease of the papain superfamily that is expressed predominantly in cytotoxic T lymphocytes and natural killer cells, where it is proposed to play a role in T-cell-mediated cytolytic activity. Unlike most cathepsins, which localise to lysosomes, Cathepsin W has been detected in the endoplasmic reticulum, suggesting a distinct intracellular trafficking and functional context. The full-length human sequence spans 376 amino acids and includes the characteristic cysteine protease catalytic domain with a conserved Cys–His–Asn catalytic triad. This recombinant is produced in HEK293 mammalian cells, providing glycosylation and folding conditions that more closely approximate native human protein than prokaryotic or insect-cell systems. HEK293 expression is particularly relevant for a protease whose activity and substrate recognition may depend on post-translational processing. In the laboratory, recombinant Cathepsin W is used as an enzyme source in substrate cleavage and activity assays designed to characterise its proteolytic specificity, as well as in inhibitor screening panels against cysteine protease inhibitor libraries. Because validated biochemical tools for CTSW remain relatively sparse in the literature, this recombinant also serves a key role as a positive control antigen for Western blot and immunohistochemistry antibody validation. Researchers requiring a paired detection reagent can cross-reference the matched Triple Point Biologics antibody (SKU: RP-CathepsinW), which has been validated for Western blot against human CTSW. The recombinant and antibody together support a complete in vitro characterisation workflow from enzymatic profiling through immunodetection.

Background

Cathepsin W (CTSW; also known as Lymphopain) is a cysteine protease with a notably restricted expression profile — transcript and protein are detected predominantly in CD8⁺ cytotoxic T lymphocytes and NK cells, in contrast to broadly expressed family members such as Cathepsins B, L, or D. Its subcellular localisation to the endoplasmic reticulum, rather than conventional lysosomal compartments, distinguishes it mechanistically from most papain-family proteases. Although its precise substrates and cleavage products in vivo remain incompletely characterised, CTSW is proposed to participate in the regulation or execution of T-cell cytolytic activity, making it of interest to researchers working on lymphocyte biology and immune effector function. CTSW has attracted growing attention in transcriptomic and multi-omic cancer studies, where its expression has been used as a proxy for cytotoxic immune infiltration. Liu X et al. (2025, Discov Oncol, PMID 41003895) applied multi-omics analysis to characterise CTSW's prognostic value and immunomodulatory role in breast cancer, framing it as an immune-related gene whose expression correlates with tumour microenvironment composition. Separately, Yu P et al. (2025, Sci Rep, PMID 39948103) included CTSW in a multi-omic analysis of programmed cell death signatures in lung adenocarcinoma, where its expression pattern across immune cell subsets was used to contextualise tumour immune landscapes. These studies treat CTSW primarily as a marker of cytotoxic lymphocyte presence and activity, underscoring the need for well-characterised recombinant protein and antibody reagents to validate detection platforms. CTSW expression has also been examined in the context of T-cell lymphoma subsets. Chennareddy S et al. (2025, Br J Dermatol, PMID 39133553) used single-cell RNA sequencing to compare molecular phenotypes across CD4⁺, CD8⁺, and TCRγδ⁺ cutaneous T-cell lymphomas, identifying subset-specific gene expression patterns in which CTSW contributed to the CD8⁺ molecular signature. Additionally, integrated transcriptomic analyses of epilepsy (Li S et al., 2025, J Immunol Res, PMID 40697415) have identified CTSW among immune-related differentially expressed genes, reflecting broader interest in CTSW as a readout of lymphocyte infiltration across disease contexts. For researchers building assay systems around CTSW — whether for substrate profiling, inhibitor characterisation, or immunodetection validation — this recombinant provides a defined, HEK293-expressed human protein suitable as both an enzymatic reagent and an antigen standard.

Applications

  • Fluorogenic substrate cleavage assay to characterise Cathepsin W cysteine protease activity
  • Inhibitor IC50 determination in cysteine protease inhibitor library screens
  • Positive control antigen for Western blot validation of anti-CTSW antibodies (pair with RP-CathepsinW)
  • Immunohistochemistry (IHC) antibody validation standard for CTSW detection in tissue sections
  • Enzyme-linked immunosorbent assay (ELISA) standard curve preparation for CTSW quantification
  • Substrate specificity profiling by positional scanning synthetic combinatorial library (PS-SCL) or mass spectrometry
  • Biophysical characterisation (SPR, ITC) of inhibitor or substrate binding to recombinant Cathepsin W

References

  1. Liu X et al. Multi-omics analysis reveals the prognostic value and immunomodulatory role of CTSW in breast cancer. Discov Oncol. 2025. doi: 10.1007/s12672-025-03550-8. PMID: 41003895.
  2. Li S et al. Integrated Transcriptomic Analysis Provided Diagnostic and Pathophysiological Insights for Epilepsy. J Immunol Res. 2025. doi: 10.1155/jimr/5925485. PMID: 40697415.
  3. Yu P et al. Comprehensive exploration of programmed cell death landscape in lung adenocarcinoma combining multi-omic analysis and experimental verification. Sci Rep. 2025. doi: 10.1038/s41598-025-87982-w. PMID: 39948103.
  4. Chennareddy S et al. Single-cell RNA sequencing comparison of CD4+, CD8+ and T-cell receptor γδ+ cutaneous T-cell lymphomas reveals subset-specific molecular phenotypes. Br J Dermatol. 2025. doi: 10.1093/bjd/ljae313. PMID: 39133553.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Lysosome

Frequently Asked Questions

What molecular weight band should I expect for recombinant Cathepsin W on SDS-PAGE or Western blot?

The full-length human Cathepsin W precursor (376 aa, UniProt P56202) has a predicted molecular weight of ~43 kDa. On reducing SDS-PAGE, our HEK293-expressed recombinant typically resolves at approximately 45–48 kDa due to N-linked glycosylation added by the mammalian expression system. If you observe a lower band (~37–40 kDa) under denaturing conditions, this likely reflects partial removal of the signal peptide and propeptide during processing. Run alongside a prestained ladder in the 35–55 kDa range. Purity is >95% by SDS-PAGE, so the dominant band should be unambiguous.

Is recombinant Cathepsin W supplied as the full-length precursor or the mature processed form?

The recombinant is produced in HEK293 cells, which support native-like signal peptide cleavage and propeptide processing. The predominant species in solution corresponds to the mature form following removal of the N-terminal signal peptide (residues 1–22) and propeptide region, yielding an active catalytic domain. The lot-specific certificate of analysis confirms the processed form by N-terminal sequencing or mass spectrometry. Because Cathepsin W is proposed to traffic through the endoplasmic reticulum rather than lysosomes, the HEK293 system more accurately recapitulates this processing compared with E. coli or baculovirus expression.

What substrates does Cathepsin W cleave and what fluorogenic substrate should I use for an activity assay?

Cathepsin W is a cysteine protease with a Cys–His–Asn catalytic triad that shows endopeptidase activity. For fluorogenic activity assays, Z-Phe-Arg-AMC (carbobenzoxy-phenylalanine-arginine-7-amino-4-methylcoumarin) is the most widely used substrate, with excitation/emission at 360/460 nm. Cathepsin W has also been reported to cleave Z-Arg-Arg-AMC, though with lower efficiency. Begin with 50–100 µM substrate and 0.1–1 µg recombinant per 100 µL reaction. Confirm activity is cysteine-protease-dependent by including 1–10 mM E-64 as a negative control inhibitor.

What is the optimal assay buffer for Cathepsin W activity and does it require activation before use?

Cysteine cathepsins require a reducing environment to maintain the active-site Cys in its thiol form. Use 50 mM sodium acetate pH 5.5–6.0, 2 mM EDTA, 5 mM DTT (or 2 mM TCEP) for maximal activity. Although the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) stabilizes the enzyme during storage, transfer to acidic assay buffer immediately before the experiment. Pre-incubate with DTT/TCEP at 37°C for 5–10 minutes before adding substrate to fully reduce the active-site cysteine. Avoid DMSO above 1% v/v, which can denature the enzyme.

What starting concentration of recombinant Cathepsin W should I use when determining inhibitor IC50 values?

For IC50 determinations, use the lowest enzyme concentration that gives a robust signal-to-noise ratio — typically 0.1–0.5 µg/mL (approximately 2–11 nM based on the ~45 kDa processed form) with 50–100 µM Z-Phe-Arg-AMC substrate in 50 mM sodium acetate pH 5.5, 2 mM EDTA, 5 mM DTT. Enzyme concentration should be kept well below the Km of your substrate to ensure the measured IC50 reflects true inhibitor potency rather than enzyme excess. Titrate enzyme across a 0.05–1 µg/mL range in a preliminary linearity experiment before committing inhibitor compound to the full concentration–response curve.

Can I use this recombinant Cathepsin W protein as a positive control for Western blot with your matched antibody?

Yes — this is a primary intended use. The matched antibody, SKU RP-CathepsinW (rabbit polyclonal, /anti-cathepsin-w-rabbit-polyclonal-antibody), was validated against this same recombinant protein in our laboratory. Loading 20–50 ng of recombinant Cathepsin W per lane on a 10–12% SDS-PAGE gel under reducing conditions gives a clean, strong band at ~45–48 kDa with RP-CathepsinW at 1:1,000–1:2,000 dilution. This positive control is particularly useful when probing cell lysates from CTL or NK cell lines where endogenous Cathepsin W expression may be low or variable.

How much recombinant Cathepsin W should I load for Western blot antibody validation alongside RP-CathepsinW?

For antibody validation lanes, 20–50 ng of recombinant per lane is sufficient to produce a clearly detectable band without saturating the signal, assuming standard ECL detection. If your cell lysate lanes contain 20–40 µg total protein, include a 30 ng recombinant lane as an adjacent reference. This directly confirms the antibody (RP-CathepsinW) is detecting the correct ~45–48 kDa species in your biological sample. Including a no-primary control alongside confirms specificity. The >95% purity of the recombinant means you will not see confounding secondary bands that could complicate interpretation.

How should I store and handle recombinant Cathepsin W to preserve activity, and what is the shelf life?

Store at -20°C in the single-use aliquots provided. The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — stabilizes the enzyme for at least 12 months at -20°C without significant loss of activity, provided freeze-thaw cycles are avoided. Do not store working aliquots at 4°C for more than 24–48 hours, as cysteine proteases are susceptible to oxidative inactivation. When thawing, place on ice rather than at room temperature and add DTT or TCEP to 1–2 mM immediately before use if proceeding to an activity assay. Carrier protein (0.1% BSA) can be added to dilute aliquots to reduce adsorptive losses at low concentrations.

Validation imagery coming soon

Western blot validation figures for REC-CathepsinW will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →